Jens Kaalby Thomsen

This inventor holds 4 USPTO granted patents and 1 published patent application and 4 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 2015-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jens Kaalby Thomsen. Retrieved from https://idiyas.com/inventor/jens-kaalby-thomsen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 4 (Patent Applications = 1)

% Patents Active = 100.0

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 21(Granted Patents)

Company Filing History:

4 out of 1,804

Novo Nordisk A/s

patents

Years Active: 2015-2020

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10583172 - HPYY(1-36) having a beta-homoarginine substitution at position 35 (2020-03-10),

2. 10246497 - Selective PYY compounds and uses thereof (2019-04-02),

3. 9085637 - Selective PYY compounds and uses thereof (2015-07-21),

4. 8937042 - Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide (2015-01-20),

Title: Jens Kaalby Thomsen: Innovator in Selective PYY Compounds

Introduction

Jens Kaalby Thomsen is a notable inventor based in Hellerup, Denmark. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of selective PYY compounds. With a total of 4 patents to his name, Thomsen's work has the potential to impact medical treatments significantly.

Latest Patents

Thomsen's latest patents include innovative compounds such as HPYY(1-36) with a beta-homoarginine substitution at position 35. This invention relates to PYY compounds that are selective Y2 receptor agonists. Additionally, he has developed PYY compounds with tryptophan substituted at position 30, which also serve as selective Y2 receptor agonists. Both inventions include pharmaceutical compositions that comprise these PYY compounds along with pharmaceutically acceptable excipients, highlighting their medical applications.

Career Highlights

Jens Kaalby Thomsen is currently associated with Novo Nordisk A/S, a leading global healthcare company. His work at Novo Nordisk has allowed him to focus on innovative solutions in the pharmaceutical industry, particularly in the area of metabolic diseases.

Collaborations

Thomsen has collaborated with notable colleagues such as Soeren Oestergaard and Kilian Waldemar Conde Frieboes. These collaborations have further enriched his research and development efforts in the field of selective PYY compounds.

Conclusion

Jens Kaalby Thomsen's contributions to the field of pharmaceuticals through his innovative patents and collaborations underscore his role as a significant inventor. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.